Efruxifermin · SYNCHRONY-Histology
Novo now owns the efruxifermin program; Akero may remain the registry sponsor. Phase 2 SYMMETRY presentations and real-world safety data are not the Phase 3 histology analysis. efruxifermin — phase 3 study in NASH With Fibrosis, MASH With Fibrosis. NCT06215716 lists Cohort 1 Only: Resolution of NASH/MASH and a ≥ 1 stage improvement in fibrosis as a primary outcome (52 Weeks). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- Primary completion is not a guaranteed topline publication or regulatory decision date.
- Registry primary completion: 2033-02 (estimated); verify independently before using it as a catalyst date.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
- The registry lists 2 primary outcome measures. A market must explicitly specify which endpoint or conjunction resolves YES; this card highlights one measure only.
Primary evidence
Phase 3 monitor — no result day confirmed
Potential outcome market
Will efruxifermin meet the prespecified primary endpoint in NCT06215716 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.